LY2090314 + FOLFOX

LY2090314 + FOLFOX is an experimental combination therapy consisting of LY2090314, a potent small molecule inhibitor of glycogen synthase kinase 3 (GSK-3), and FOLFOX, a well-established chemotherapy regimen that includes folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. LY2090314 targets the GSK-3 pathway to increase β-catenin signaling, potentially sensitizing tumor cells to cytotoxic agents. FOLFOX exerts antineoplastic activity by causing DNA damage (via oxaliplatin) and inhibiting DNA synthesis (via 5-FU). This combination is under investigation primarily for advanced solid tumors, with a scientific rationale centered on synergistic antitumor effects.